Editor’s Note: CRE has long warned about a wide-scale expansion of competitive bidding.
From: HME News
WASHINGTON – The Office of Inspector General (OIG) recommends in a new study that CMS change the way it pays for home infusion drugs.
One of the options laid out by the OIG: Include home infusion drugs in the next round of competitive bidding. While external infusion pumps and supplies were included in the Round 1 re-compete (but not Round 1 or Round 2), CMS has not included drugs at all. CMS concurred with this recommendation.